Research Study

A Phase III, Multicentre, Randomised, Double Blind, Parallel Group, Placebo Controlled Study To Assess The Efficacy And Safety Of One Or More Intradetrusor Treatments Of 600 Or 800 Units of Dysport® For The Treatment Of Urinary Incontinence In Subjects With Neurogenic Detrusor Overactivity Due To Spinal Cord Injury Or Multiple Sclerosis
Principal Investigator 
Lynn Stothers

Overview

ClinicalTrials.gov# 
NCT02660138
Status 
Recruiting
Study Start/End 
Nov 29, 2016 to Jul 25, 2017
Locations 
Diamond Health Care Centre, ICORD – Blusson Pavilion
Name/Title 
Ivy Allard, Research Nurse
Phone 
604-875-4111 ext.69876
Email Address 
ivy.allard@vch.ca
Purpose of Study 

The purpose of this study is to provide confirmatory evidence of the safety and efficacy of two Dysport® (AbobotulinumtoxinA) doses (600 units [U] and 800 U), compared to placebo in reducing urinary incontinence (UI) in adult subjects treated for neurogenic detrusor overactivity (NDO) due to spinal cord injury (SCI) or multiple sclerosis (MS).

Eligibility 

Visit ClinicalTrials.gov for more information. 

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific research studies only. If you have specific questions which require clinical expertise, please call your primary care physician.